High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-01-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: donorcelltransplantallogeneictransplantation
  Phrases that lowered it: bortezomibclinicaltrialrelevantmale
• Sponsor's past termination rate: 20.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 146 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 339 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 24249 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 137775 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.0% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 90.0% (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis NCT01860170 · started 2012 · scored riskier than 94% of active trials completed
• A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients NCT01926899 · started 2013 · scored riskier than 74% of active trials completed
• Bortezomib in Patients With Chronic Graft Versus Host Disease NCT01672229 · started 2012 · scored riskier than 93% of active trials completed
• Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention NCT04503616 · started 2020 · scored riskier than 79% of active trials completed
• Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma NCT00992446 · started 2010 · scored riskier than 76% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.